

RNS Number: 8114X

Cross Shore Acquisition Corporation

05 June 2007

Cross Shore Acquisition Corporation

5 June 2007

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Cross Shore Acquisition Corporation

Posting of Readmission Document

Proposed merger of Cross Shore Acquisition Corporation with

Research Pharmaceutical Services Inc.

Change of name to Research Pharmaceutical Services Inc.

Notice of Special General Meeting

and

Application for Re-admission

Overview

Cross Shore Acquisition Corporation ('Cross Shore') announces that it has today posted its Re-admission Document in connection with its proposed merger with ReSearch Pharmaceutical Services, Inc. ('RPS'), a provider of integrated clinical development solutions to the bio-pharmaceutical industry, which was announced on 27 April 2007.

Pursuant to the Acquisition Agreement, the Selling Securityholders will receive, in aggregate, \$39.1 million in cash, 12.55 million Exchange Shares and 19.06 million Exchange Warrants. In addition, approximately \$2.6 million will be paid, on or prior to completion of the Acquisition, to holders of RPS preferred stock as accrued and unpaid dividends, approximately \$4.5 million of RPS subordinated debt will be repaid and existing options to purchase shares of RPS common stock will be converted into options to purchase Shares. Further, it is expected that on completion of the Acquisition, the Company will assume all of the remaining outstanding bank debt of RPS, which, as at 31 May 2007, had a principal balance of \$8.7 million and an average month end balance for the preceding 6 months of \$9.0 million.

The payment of \$39.1 million assumes that holders of RPS options do not exercise those options prior to completion of the Acquisition. If vested RPS options are exercised then, pursuant to the Acquisition Agreement, each RPS share of common stock acquired upon such exercise will entitle the holder of such share to receive \$8.00 in cash in exchange for such share.

The Acquisition will constitute a reverse takeover under the AIM Rules and meets the criteria established for a qualified business combination under the Company's charter. Completion of the Acquisition is conditional upon, inter alia, the approval of Shareholders at a Special Meeting to be held on July 11, 2007. If the Acquisition is approved at the Special General Meeting, trading in the Existing Shares and Existing Warrants on AIM will be cancelled and application will be made for the admission to trading on AIM of the Enlarged Issued Share Capital and the Increased Warrants.

In connection with the Acquisition, Shareholders will be asked to approve a number of other matters, including changing the name of the Company to 'Research Pharmaceutical Services Inc.' The Company is expected to trade as RPS and change its name to ReSearch Pharmaceutical Services, Inc.

Copies of the Re-admission Document will be available free of charge at the offices of Arbuthnot Securities Limited, Arbuthnot House, 20 Ropemaker Street, London EC2Y 9AR, United Kingdom during normal business hours on any weekday (Saturdays, Sundays and public holidays excepted) until 11 July 2007.

The Company's Shares (AIM: CSE) and Warrants (AIM: CSEW) will resume trading concurrently with this announcement.

Reasons for the Acquisition

The Board of Cross Shore believes that the acquisition of RPS represents an excellent investment opportunity for the Company and its Shareholders for the following reasons:

RPS Highlights

* Large and Growing Market: The world's largest bio-pharmaceutical companies spend more than 15 per cent. of sales on R&D. Total R&D

expenditure is expected to grow to more than \$100 billion by 2009. Phase II and Phase III development, RPS' target market, is estimated to grow to \$28 billion by 2009.

- * Strong Fundamentals: Demand for outsourced development solutions in the bio-pharmaceutical industry remains strong and should continue to benefit from a number of trends including the globalization of trials, increased clinical trial complexity and cost-cutting pressure on bio-pharmaceutical companies.
- * Next Generation Outsourcing: RPS is the industry's first PRO - an integrated resourcing and management solution working within the R&D infrastructure of pharmaceutical companies.
- * Fast-Paced Growth: RPS has experienced growth in the past several years, particularly since late 2005, with the adoption of the RPS model by several of the world's leading bio-pharmaceutical companies:
 - Net revenue grew at a compounded annual growth rate of approximately 37 per cent. from 2000 to 2006.
 - Net revenue in 2006 was \$84.4 million, up 34 per cent. over 2005 and unaudited net revenues for the first quarter of 2007 totaled \$26.0 million, representing year-on-year growth of 45.9 per cent when compared with the first quarter of 2006.
 - EBITDA in 2006 was \$4.0 million, up \$3.7 million over 2005. Unaudited EBITDA in the fourth quarter of 2006 was approximately \$1.3 million. Unaudited EBITDA in the first quarter of 2007 was \$1.6 million, up from \$0.6 million in the first quarter of 2006.
- * Customer Backlog: RPS entered 2007 with contracted net revenue backlog of \$72.3 million, representing a 41 per cent. increase over the end-of-year backlog in 2005.
- * Blue Chip Validation of Innovative Business Model: RPS introduced the PRO model in 1998 and is now successfully implementing this model with four of the world's top twelve bio-pharmaceutical companies and five 'mid-sized' companies, demonstrating acceptance from some of the largest and most respected companies in the bio-pharmaceutical industry.
- * Expanding the Market: Pharmaceutical companies are expected to outsource approximately \$6 billion of the \$28 billion market estimated expenditures in 2009 for Phase II and III drug development to traditional CROs. RPS' integrated functional approach primarily targets the \$22 billion expenditure in these development phases conducted in-house by large bio-pharmaceutical companies.
- * Globalization - the Next Value Creating Opportunity: The resources provided by Cross Shore, in terms of capital and experience in business process outsourcing and M&A in Asia, may help RPS to capitalize on strategic opportunities and establish the company as a global solution for its customers.
- * Platform for Significant Operational Leverage and International Growth: RPS combines clinical functional execution and experience with industry-focused staffing engines, providing what the Directors and Proposed Directors believe to be the management skills and talent required by bio-pharmaceutical companies in support of clinical trials across their pipeline. As of the date of this document, RPS has an experienced pool of clinical research associates with a total staff of more than 1,000 individuals possessing the core skills required by pharmaceutical companies for their clinical trial initiatives.
- * Proven and Experienced Operational Management: RPS' management team has corporate and entrepreneurial experience in core clinical, project management and outsourcing functions required in a fast-growth operating environment.

The Directors and the Proposed Directors believe that RPS may benefit from the application of Cross Shore's expertise and resources, particularly in the area of expanding global solutions in certain geographic areas targeted for expansion.

Management

It is proposed that, upon completion of the Acquisition, the Enlarged Board will initially be comprised of seven individuals of whom three will be drawn from Cross Shore's existing Directors and four from RPS' existing directors as follows:

- * Daniel M. Perlman (Chief Executive Officer and Chairman of the Board)
- * Edward V. Yang (Executive Director)
- * Harris Koffer, Pharm.D. (President, Chief Operating Officer and Executive Director)
- * Dennis M. Smith (Executive Director)

- * Daniel Raynor (Non-Executive Director)
- * Stephen E. Stonefield (Non-Executive and Independent Director)
- * James R. Macdonald (Non-Executive Director)

Jon A. Burgman, an existing independent Director of Cross Shore, will step down from the Board on completion of the Acquisition. In addition, the Company intends, and has undertaken to Arbutnot, to appoint a further independent Director within six months following Re-admission. If the resolution to increase the permitted size of the Board, to be proposed at the Special General Meeting is not approved, upon completion of the Acquisition the Board will be made up of the following five directors: Daniel M. Perlman, Edward V. Yang, Harris Koffer, Dennis M. Smith, and Daniel Raynor.

About RPS

Headquartered in Pennsylvania, RPS is a provider of integrated clinical development outsourcing solutions to the bio-pharmaceutical industry. RPS' services are provided in connection with the design, initiation and management of clinical trials programs, a critical element in obtaining regulatory approval for bio-pharmaceutical products. RPS' PRO model combines the capabilities of a specialty staffing organization with the expertise of a clinical research organisation (CRO) enabling RPS to offer a model that is gaining traction in the market.

RPS attempts to develop strong strategic relationships with its clients at the senior levels of an organization and then designs customized outsourcing solutions that 'carve out' key functional areas of the client's clinical development infrastructure to be outsourced to RPS. The PRO solution emphasizes close integration with the client so that the client can selectively outsource (1 of 4)

{ those areas in which the greatest savings can be realized while permitting the client to maintain control of the key medical and regulatory decision-making processes.

Summary financial information on RPS

The summary financial information for RPS for the financial years 2004 to 2006 set out below has been extracted, without adjustment, from the audited financial information for financial years 2004 to 2006.

For the year ended December 31 (figures in 000's)

	2004	2005	2006
	----	----	----
Net revenues	\$63,043	\$62,799	\$84,417
Gross profit	\$16,803	\$17,055	\$23,052
EBITDA	\$937	\$308	\$3,983
Net income / (loss) after tax	\$(787)	\$(1,683)	\$1,792
Net Assets	\$3,278	\$1,729	\$3,652
Net revenue growth	27.1%	(0.4)%	34.4%
Gross margin	26.7%	27.2%	27.3%
SG&A per cent.	25.2%	26.7%	22.6%
EBITDA margin	1.5%	0.5%	4.7%

For the 3 months ended March 31, 2007, RPS generated unaudited EBITDA of \$1.6 million on unaudited net revenues of \$26.0 million.

About Cross Shore

Cross Shore was founded in 2006 by Ed Yang and Dennis Smith to serve as a vehicle for the acquisition of all or part of one or more operating companies engaged in the delivery of business services to companies and consumers in the U. S.

Ed Yang, Cross Shore's Chairman, was formerly SVP and President of Asia Pacific Region for Electronic Data Systems from 1992 to 2000, and prior to that, SVP and President of Asia Pacific and Latin America for Wang Laboratories.

Dennis Smith lived and worked in Asia from 1978 to 2005 and founded Vsource Asia, one of Asia's first business process outsourcing companies, in 2000 and ChinaVest, one of the first private equity firms focused on investment in Greater China, in 1985.

Shares and Warrants in issue after the Transaction

Immediately following Re-admission, the Company is expected to have 35.9 million common shares and 56.4 million Warrants in issue, assuming no exercise of Existing Warrants and no exercise of Repurchase Rights and subsequent cancellation of Shares by the Company.

Lock-in agreements

On Re-admission the Directors, the Proposed Directors and their respective associates will be interested in an aggregate of 7.11 million Shares representing 19.8 per cent. of the Enlarged Issued Share Capital (assuming no exercise of Existing Warrants and no exercise of Repurchase Rights and subsequent cancellation of Shares by the Company), an aggregate of 5.03 million Warrants representing 8.9 per cent. of the Increased Warrants (assuming no exercise of the Existing Warrants), and an aggregate of 1.56 million options to acquire Shares of the Company.

In accordance with Rule 7 of the AIM Rules, all of the Directors and officers and their related parties (as such term is defined in the AIM Rules) agreed at the time of the Initial Public Offering not to dispose of any Shares or Warrants for one year from 28 April 2006 being the date of the admission of the Company to trading on AIM. In addition, all of the Founding Shareholders (including the Directors) have placed their Founding Shares into an escrow account maintained by Collins Stewart (CI) Limited, acting as escrow agent. Subject to certain limited exceptions set forth in the escrow agreement between the Founding Shareholders and Collins Stewart (CI) Limited as escrow agent, these Founding Shares may not be transferred and may not be released from the escrow until 24 April 2009. In connection with Re-admission, the Escrow Founding Shareholders and the Company have agreed, for the benefit of Arbuthnot, that they will comply with the terms of this escrow agreement.

In addition, as a condition precedent to the completion of the Acquisition, the Directors (with the exception of Jon Burgman) and the Proposed Directors have undertaken to Arbuthnot and the Company not to dispose of any Shares or Warrants for a period of 12 months from Re-admission and thereafter for a further 12 months not to dispose of interests in Shares or Warrants held by them on the date of Re-admission without the consent of Arbuthnot, subject to certain limited exceptions. Daniel Perlman's lock-in agreement, the entering into of which is a condition precedent to the completion of the Acquisition, provides that the lock-in period applicable to his Shares will be the shorter of 12 months from Re-admission and the date on which either his employment with the Company or service as a director of the Company is terminated.

In addition, Argentum Capital Partners, L.P., Argentum Capital Partners II, L.P., The Productivity Fund IV, L.P. and The Productivity Fund IV, Advisors Fund, L.P., who on Re-admission will be the holders of 6.83 million Shares in aggregate and an aggregate of 10.38 million Warrants, shall have, as a condition precedent to the completion of the Acquisition, undertaken to Arbuthnot and the Company not to dispose of any Shares or Warrants for a period of 12 months from Re-admission and thereafter for a further 12 months not to dispose of interests in Shares or Warrants held by them on the date of Re-admission without the consent of Arbuthnot, subject to certain limited exceptions.

Certain disposals are permitted under the terms of these lock-in agreements, including disposals with the approval of the other locked-in parties and the consent of Arbuthnot, and disposals in the event of an intervening court order, the death of a party that is subject to these lock-in arrangements and in respect of the giving of an irrevocable undertaking in respect of, or an acceptance of, a take-over offer for the Company which is open to all shareholders.

Contingent Dividend

Depending on the extent to which Existing Shareholders elect to exercise their Repurchase Rights and the extent to which holders of RPS options exercise such options prior to completion of the Acquisition, the Board may, at its discretion, declare a dividend of up to \$1.00 per Share up to a maximum of \$18,666,668, payable to Existing Shareholders (other than holders of Founding Shares) who do not elect to exercise their Repurchase Rights. There can be no assurance that any dividend will be declared or, if one is declared, the amount of such dividend. Further details are set out in the Re-admission Document.

Repurchase Rights

Each Existing Shareholder holding Existing Shares issued in the Company's Initial Public Offering or purchased following such offering in the open market has the right to vote against all or any of the proposed Special Meeting resolutions and, if voting against the resolution to approve the Acquisition, require that the Company repurchase all of such Existing Shareholder's Shares. If an Existing Shareholder exercises its Repurchase Rights it will be paid an amount in cash at a price equal to the Repurchase Rights Price Per Share. The Founding Shareholders have agreed that, in the event that any Existing Shareholders exercise their Repurchase Rights, an amount of Founding Shares held by the Founding Shareholders will also be repurchased by the Company such that at no time will the Founding Shares represent an aggregate of more than 25 per cent. of the outstanding Shares.

However, if the proposed Acquisition is not completed for any reason, then there will be no repurchase of Existing Shares even if an Existing Shareholder has so elected. If the Company does not have an amount of cash at completion of the

Acquisition at least equal to the Target Closing Cash after satisfaction of the Closing Payments (including any payments made to Shareholders as a result of the exercise of Repurchase Rights), the Acquisition may not be capable of completion. It is possible, therefore, that the Acquisition may not be capable of completion if Shareholders exercise Repurchase Rights in respect of more than 3.80 million Shares, assuming that all vested RPS options are exercised prior to completion of the Acquisition and all transaction costs are paid.

Enquiries:

Cross Shore Acquisition Corporation
Dennis Smith / Ed Yang

Telephone: +1 843 597 4760

Arbuthnot Securities Limited (Nomad and UK Broker to Cross Shore)

James Steel / Guy Blakeney

+44 (0)20 7012 2000

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Publication of this document	5 June 2007
Announcement of Acquisition and resumption of trading in the Existing Shares and Existing Warrants on AIM	5 June 2007
Special Meeting Record Date	1 July 2007
Latest time and date for receipt of Forms of Proxy	12 pm London Time, 10 July 2007
Special Meeting	10am Central Daylight Time, 11 July 2007
Completion of the Acquisition	13 July 2007
Re-admission and commencement of dealings in Enlarged Issued Share Capital and Increased Warrants becomes effective	8:00 am London time, 16 July 2007

The above times and dates are indicative only and may be subject to change. In the event that the expected timetable set out above changes, the Company will notify such amended dates through the Regulatory Information Service of the London Stock Exchange. Times and dates referred to in this document are times and dates prevailing in London, England unless otherwise stipulated.

ACQUISITION STATISTICS(1)

Consideration payable upon completion of the Acquisition(2)	\$46.2 million in cash(3)
	12.55 million new Exchange Shares
	19.06 million new Exchange Warrants
Exchange Shares as a percentage of Enlarged Issued Share Capital	35.0 per cent. (4)
Exchange Warrants as a percentage of Increased Warrants	33.8 per cent. (5)
RPS consolidated net revenues for the year ended 31 December 2006	\$84.4 million
RPS consolidated net income for the year ended 31 December 2006 (2 of 4)	\$1.8 million
{ RPS consolidated EBITDA for the year ended 31 December 2006	\$4.0 million
International Securities Identification Number of the Shares	USU1549T1098
International Securities Identification Number of the Warrants	USU1549T1171

(1) All numbers are approximate.

(2) In addition, it is expected that on completion of the Acquisition, the Company will assume the outstanding bank debt of RPS, which for the month ended April 30, May 31, 2007 had a principal balance of \$8.7 million and an average

month end balance for the 6 months preceding the date of this document of \$9.0 million. Furthermore, the Company will grant 2.25 million options to acquire Shares to current holders of RPS options in exchange for their RPS options. These new options have a weighted average exercise price of \$0.68 per Share.

(3) Of this amount, \$39.1 million will be paid to the Selling Securityholders pursuant to the Acquisition Agreement, \$2.6 million will be paid, at or prior to completion of the Acquisition, to holders of RPS preferred stock as accrued and unpaid dividends and approximately \$4.5 million will be used to fully repay RPS' outstanding subordinated debt. This amount assumes that holders of RPS options do not exercise those options prior to completion of the Acquisition. If RPS options are exercised then, pursuant to the Acquisition Agreement, each RPS share of common stock acquired upon such exercise will entitle the holder of such share to receive \$8.00 in cash in exchange for such share.

(4) Assuming no exercise of Existing Warrants and no exercise of Repurchase Rights and subsequent cancellation of Shares by the Company. This represents the Exchange Shares as a percentage of the Enlarged Issued Share Capital. Pursuant to the Acquisition Agreement, options to acquire shares of RPS common stock will be converted into options to acquire 2.25 million Shares. These options, the Warrants and the Sunrise option described in footnote vi below are not included in calculating this amount.

(5) Assuming no exercise of the Existing Warrants.

DEFINITIONS

' Acquisition'	the proposed acquisition by the Company of RPS pursuant to the Acquisition Agreement through the merger of Acquisition Sub with and into RPS with RPS being the surviving corporation, followed by the merger of the surviving corporation with and into Second Acquisition Sub
' Acquisition Agreement'	the conditional agreement and plan of merger among the Company, Acquisition Sub, RPS, the Selling Securityholders and Daniel M. Perlman and Daniel Raynor as the Selling Securityholders Committee dated 26 April 2007, relating to the Acquisition
' Acquisition Sub'	Longxia Acquisition, Inc., incorporated in Pennsylvania under the Pennsylvania Business Corporation Law of 1988
' AIM'	AIM, a market operated by the London Stock Exchange
' AIM Rules'	the rules of AIM as set out in the publication entitled 'AIM Rules for Companies' published by the London Stock Exchange from time to time
' Company' or ' Cross Shore'	Cross Shore Acquisition Corporation, incorporated in Delaware under the General Corporation Law of the State of Delaware
' Contingent Dividend'	a dividend which may be declared by the Company in conjunction with the Acquisition of up to \$1.00 per Existing Share, not to exceed \$18,666,668 in the aggregate
' Continuing Directors'	Edward V. Yang, Dennis M. Smith and Stephen E. Stonefield
' Directors'	the directors of the Company as of the date of this announcement
' Enlarged Board'	the directors of the Company upon and immediately following Re-admission, being the Continuing Directors and the Proposed Directors
' Enlarged Group'	the Company and its subsidiary undertakings following the Acquisition
' Enlarged Issued Share Capital'	the Shares issued and outstanding immediately following Re-admission
' Escrow Founding Shareholders'	Founding Shareholders with the exception of Sunrise
' Excess Cash'	(a) the amount by which the cash held by the

	Company after payment of, or provision for payment of, the Closing Payments exceeds Target Closing Cash minus (b) the aggregate amount of any consideration paid or payable to holders of options to purchase shares of RPS common stock who exercise such options after the execution of the Acquisition Agreement but prior to the completion of the Acquisition
' Exchange Securities'	the Exchange Shares and the Exchange Warrants
' Exchange Shares'	the new Shares of the Company to be issued to the Selling Securityholders as partial consideration for the Acquisition
' Exchange Warrants'	the new Warrants of the Company to be issued to the Selling Securityholders as partial consideration for the Acquisition
' Existing Shares'	the 23,333,335 Shares issued and outstanding on the date of this announcement
' Existing Shareholders'	Shareholders immediately prior to Re-admission
' Existing Warrants'	the 37,333,336 Warrants issued and outstanding on the date of this announcement
' Founding Shareholders'	those persons who hold, directly or indirectly, Founding Shares
' Founding Shares'	4,666,667 Shares in issue subscribed for by the Directors (and/or their affiliates) and Sunrise
' Increased Warrants'	the Existing Warrants and the Exchange Warrants
' Initial Public Offering'	the initial public offering of Shares and Warrants in connection with the Original Admission to trading on AIM on 28 April 2006
' Proposed Directors'	the proposed directors of the Company whose names are set out at page * of this Document
' Re-admission'	admission to trading on AIM of the Existing Shares, the Existing Warrants and the Exchange Securities becoming effective in accordance with the AIM Rules
' Re-admission Document'	The re-admission document dated 5 June 2007 published by the Company in connection with Re-admission
' Repurchase Rights'	the right of an Existing Shareholder to vote against a proposed acquisition by the Company and require the Company to repurchase the Existing Shares owned by such Existing Shareholder at the Repurchase Rights Price Per Share
' Repurchase Rights Price Per Share'	\$5.50 per Existing Share, plus the pro rata portion of interest earned on the Trust Fund
' RPS'	ReSearch Pharmaceutical Services, Inc., a company incorporated in Pennsylvania
' Second Acquisition Sub'	ReSearch Pharmaceutical Services, LLC
' Selling Securityholders'	securityholders of RPS selling securities of RPS pursuant to the Acquisition Agreement
' Shareholder'	a holder of Shares
' Shares'	common shares of \$0.0001 each in the capital of the Company
' Special Meeting'	the special general meeting of Shareholders to be held on 11 July 2007
' Sunrise'	Sunrise Securities Corp.
' Target Closing Cash'	\$30,000,000 minus one-half of the aggregate amount of any consideration paid or payable to holders of options to purchase shares of

RPS common stock who exercise such options after the execution of the Acquisition Agreement but prior to the completion of the Acquisition

' Trust Fund'

the trust fund into which certain proceeds of the initial public offering of the Company were received and are held in trust by the Trustee, pursuant to the investment management agreement between the Company and the Trustee dated 24 April 2006

' Trustee'

Continental Stock Transfer and Trust Company

' Warrants'

warrants, each entitling the registered holder thereof to purchase one Share at a

(3 of 4)

{

price of \$5.00 per Share (subject to adjustment in certain circumstances), at any time from the completion of the Acquisition until the earlier of 24 April 2010 and redemption by the Company, which redemption may take place at any time after the Acquisition with the prior consent of Sunrise: (a) in whole and not in part; (b) at a price of \$0.0001 per warrant; (c) upon a minimum 30 days prior written notice of redemption; and (d) if, and only if, the last independent bid price of Shares equals or exceeds \$8.50 per Share for any 20 trading days within a 30 trading day period ending three business days before the Company sends notice of redemption and the weekly trading volume of Shares has been at least 550,000 Shares for each of the two calendar weeks before such notice of redemption has been sent

This announcement does not constitute, or form part of, an offer or an invitation to purchase any securities.

This announcement is not for distribution into the United States, Canada, Japan, Australia, the Republic of Ireland or the Republic of South Africa or any other jurisdiction where its distribution would constitute a violation of the relevant laws of such jurisdiction. Neither Cross Shore Shares nor the Cross Shore Warrants have been registered under the United States Securities Act of 1933, as amended, or under the applicable securities laws Canada, Japan, Australia, the Republic of Ireland or the Republic of South Africa. Accordingly (subject to certain exceptions), neither the Cross Shore Shares nor the Cross Shore Warrants may, directly or indirectly, be offered or sold within the United States, Canada, Japan, Australia, the Republic of Ireland or the Republic of South Africa or to or by any national, resident or citizen of such countries. The distribution of the Readmission Document in other jurisdictions may be restricted by law and therefore persons into whose possession the Readmission Document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities law of any such jurisdictions.

Arbuthnot Securities Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as nominated adviser and UK broker to the Company in connection with Re-admission. Its responsibilities as the Company's nominated adviser under the AIM Rules are owed solely to the London Stock Exchange and are not owed to the Company or to any Director or Proposed Director or to any other person.

Arbuthnot Securities Limited is acting exclusively for the Company and for no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or the Re-admission. No representation or warranty, express or implied, is made by Arbuthnot Securities Limited as to the contents of this announcement. The information contained in this announcement is not intended to inform or be relied upon by any subsequent purchasers of Cross Shore Shares or Warrants (whether on or off exchange) and accordingly no duty of care is accepted in relation to them.

The Directors and Proposed Directors of Cross Shore Acquisition Corporation accept responsibility, individually and collectively, for the information contained in this announcement and for compliance with the AIM Rules. To the best of the knowledge and belief of the Directors and Proposed Directors, who have taken all reasonable care to ensure that such is the case, the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.